Cleo Diagnostics (ASX:COV) ROCE % : -107.74% (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cleo Diagnostics's annualized ROCE % for the quarter that ended in Dec. 2023 was -107.74%.

Cleo Diagnostics ROCE % Historical Data

The historical data trend for Cleo Diagnostics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics ROCE % Chart

Cleo Diagnostics Annual Data

Trend

Jun23

ROCE %

Cleo Diagnostics Semi-Annual Data
	Dec22	Jun23	Dec23
ROCE %	-	-	-107.74

Cleo Diagnostics ROCE % Calculation

Cleo Diagnostics's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: . 20 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: . 20 )		(A: Jun. 2023 )
	=		/	( ( ( - )	+	( - ) )	/ )
	=		/	( (	+	)	/ )
	=		/
	=	%

Cleo Diagnostics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-5.17	/	( ( (1.077 - 2.02)	+	(10.739 - 0.199) )	/ 2 )
	=	-5.17	/	( ( -0.943	+	10.54 )	/ 2 )
	=	-5.17	/	4.7985
	=	-107.74 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Cleo Diagnostics (ASX:COV) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cleo Diagnostics ROCE % Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cleo Diagnostics (ASX:COV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000

Website

https://www.cleodx.com

Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines